Capturing the future of antibodies.

Zepteon, Inc. is a privately held corporation that has developed first-in-class chromatography resins capable of separating antibodies and Fc-fusions with specific glycoforms that can more potently combat infectious diseases, cancer, autoimmunity and rare diseases.

Our Goal

Zepteon's goal is to build technologies that enable research, development and production of transformative medicines. Our technology can be used to streamline the development of Biosimilars, enhance the effectiveness of Biobetters and enable novel plasma derived (IVIG) therapeutics.

Established in 2012

Since spinning out of a large pharmaceutical company, Zepteon has launched Glycap-3A chromatography resin capable of separating nonfucosylated or bisected IgG glycorforms, built a large customer base and has been granted patents in the US (US10221210B2), EU (EP2734537A1) and other regions. ​

Our Team

Austin Boesch, PhD
CEO

Austin is co-founder of Zepteon and has over two decades of R&D and drug discovery experience in the biopharmaceutical field.  At Millipore he was integral to the development of a commercially available virus retention filter. At Pfizer he performed process development for clinical pipeline and commercially launched biomolecules. At Torque Therapeutics he was pivotal in shepherding an ex vivo IL-15 nanoparticle-tethered T cell therapy from research to Phase I and lead discovery efforts for a liposomal-based TLR7/8 agonist program. At Tidal Therapeutics (acquired by Sanofi in 2021) he developed and lead the LNP-targeting and mRNA payload discovery efforts for in vivo reprogramming and was Program Head for the first in vivo CAR-T therapy. Austin was an Innovation fellow at the Thayer School of Engineering at Dartmouth College where he received his PhD in Bioengineering with a focus in designing proteins to modulate the cellular arm of the immune system. He has more than 25 publications and patents.

Glen Bolton, PhD
COO

Glen is co-founder of Zepteon, has a PhD in chemical engineering from MIT and also received training in marketing, finance, accounting, economics, leadership and organizational behavior while at MIT. He has more than 15 years of protein purification and project management experience in the pharmaceutical industry. He helped lead the commercialization of two protein purification products during his tenure at Millipore. He developed and validated the purification processes for multiple early and late stage clinical antibodies while at Pfizer, Biogen, and Amgen. In addition, he has developed the purification processes for biosimilar antibodies with targeted glycosylation profiles. He taught the Protein Purification and Cell and Microbe Cultivation courses at Tufts. He has more than 30 publications and patents, has served on two Parenteral Drug Association task forces, and was the industrial chair of the BIOT division of the 2014 American Chemical Society Conference.

​

Strategic Advisors

Maria Grunwald is an executive in the life science industry with more than 15 years of experience in business development and licensing. She has held senior roles at Radius Health and Dyax and has gained deep transactional expertise, in particular in strategic partnering. Other companies include AesRx, IsoPlexis, Windgap Medical, Dicerna and QurAlis. In 2009, she was named a mentor for the MIT Venture Mentoring Service. Maria received graduate degrees from the Universities of Hannover and Cologne and performed her Ph.D. studies in neuroscience at the Johns Hopkins University School of Medicine. She also holds an MBA from the MIT Sloan School of Management.

Tom Ransohoff has over twenty years in the biopharmaceutical industry, in areas ranging from product and technology development to cGMP manufacturing. In addition to his previous leadership roles at Tarpon Biosystems and at BioFlash Partners LLC wher he served as CEO, Mr. Ransohoff is a Senior Consultant with Bioprocess Technology Consultants, a leading biopharmaceutical CMC consulting firm. Mr. Ransohoff's previous experience includes senior positions with business unit and operational responsibility at TranXenoGen, Dyax, Repligen, and Xoma. Mr. Ransohoff has a Bachelor's degree from MIT and a Master's degree from UC-Berkeley, both in Chemical Engineering.

Marc Silver is a senior executive with broad ranging business management skills gained from over 25 years’ experience in the biopharmaceutical industry. He has developed a range of funded initiatives including new company business plans and new company programs and has a deep track record of transaction negotiation including “out-licensing”, “in-licensing”, partnering and financing. Marc was the VP of business development at BioWa from 2009-2012 and has an MBA from MIT.
​
Ronald Sia has served as an attorney for seven years at Procter & Gamble and Gillette. He has handled supporting a global $1 billion business and provided business guidance on innovation and commercial strategies across new products and base business initiatives. He has served as the lead attorney on multiple domestic and foreign disputes including advertising challenges and patent infringement cases. He has received a JD from UNH and a BS in chemical engineering from Tufts University.